22 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. It has seen positive findings from early trials for FT500, preventing disease progression for 11 out of 15 patients, something that has kept the stock price buzzing of late. And the recent stock price growth means that some of the positives are already priced in at the current price of $114. HighTower Advisors LLC boosted its holdings in shares of Fate Therapeutics by 5.9% in the 1st quarter. However, the company saw a 62% growth in total shares outstanding due to share issuances, resulting in only a 61% growth in revenue per share to $0.16 in 2019, compared to $0.10 in 2017. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com. By Alex Keown. Get the free daily newsletter read by industry experts. Per deal terms, J&J will buy $50 million Fate shares at $31 apiece,a roughly 47% premium to Fate's $21.07 closing price on Thursday. What happened When Celgene announced it was acquiring Juno. Answer: The average return after a rise is understandably lower than a fall as detailed in the previous question. Identify stocks that meet your criteria using seven unique stock screeners. By creating a free account, you agree to our, In Britain, warm hubs emerge to beat soaring energy costs, In Chicago, adapting electric buses to winters challenges, Global race to boost electric vehicle range in cold weather, Ukraine ally Kallas fights for reelection in Estonia vote, Paid express lanes grow more popular in once-reluctant South, Pot vote has Oklahoma hungry to rake in green from Texas, Home Depot Stock Earnings Slide, Long Term Value Still There, AbbVie Stock Still a Solid Buy Despite Challenges, President, Chief Executive Officer & Director, Chief Financial Officer & Accounting Officer, Senior Vice President-Technical Operations. Eight of 11 lymphoma patients who received one Fate NK cell therapy, FT516, have shown evidence of a response, as have 10 of 14 given . She looks for companies that are changing the . According to the Trefis Machine Learning Engine, which identifies trends in a companys stock price using historical stock data, returns for FATE stock average around 6% in the next one-month (twenty-one trading days) period after experiencing a 5% fall in a week (five trading days). Fate Therapeutics is currently working on multiple programs, including FT500, FT516, FT-ONO2, and FATE-NK100 for the treatment of advanced solid tumors, and the developments around the clinical trials for these treatments has kept its stock buzzing of late. Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Segall Bryant & Hamill LLC's holdings in Fate Therapeutics [] Here's what Wall Street expects from Fate Therapeutics's earnings report, Fate Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates, Fate Therapeutics GAAP EPS of -$0.58 beats by $0.29, revenue of $44.34M beats by $25.93M, FATE's Q4 Loss Narrower Than Expected, Pipeline in Focus, Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $26.14, NK Cell Therapy Market 2023 to 2026 CONSUMER INSIGHTS with Dynamics Scenario, Induced Pluripotent Stem Cells (iPSCs) Market Size, Share & Trends Analysis Forecast Report by 2028, Fate Therapeutics (NASDAQ:FATE) Stock Price Down 7%, Natural Killer Cell Therapy Market Size 2023 NEWEST INDUSTRY DATA with Recent Industry Developments till 2028, Natural Killer Cell Therapy Market (New Insights Report) By 2023 which is Booming Strong Growth in the Globe till 2028, FATE Investors Have Opportunity to Lead Fate Therapeutics, Inc. Securities Fraud Lawsuit, Fate Therapeutics, Inc. (FATE) Class Action: Contact Robbins LLP for Information Regarding the Class Action and Lead Plaintiff Deadline, Outset Medical, SolarEdge Technologies And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session, Needham Reaffirms Their Buy Rating on G1 Therapeutics (GTHX), Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2022 Financial Results, ALERT: Investors in Fate Therapeutics, Inc. with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - FATE, CLASS ACTION UPDATE for AVYA, FATE and PHI: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, CLASS ACTION UPDATE for ENVX, YMAB and FATE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders, view top-rated stocks among Wall Street analysts, 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). Get daily stock ideas from top-performing Wall Street analysts. Fate Therapeutics Reviews - Glassdoor Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more. AlphaCrest Capital Management LLC Trims Position in Best Buy Co., Inc. AlphaCrest Capital Management LLC Sells 26,238 Shares of Hormel Foods Co. Burlington Stores, Inc. Shares Sold by Eaton Vance Management. Quantbot Technologies LP bought a new stake in shares of Fate Therapeutics during the 3rd quarter valued at about $69,000. Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. 2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. You may opt-out by. Zscaler, Inc Plummets, Is It Time To Buy The Dip? UBS Group AG Reduces Stock Holdings in Builders FirstSource, Inc. Boothbay Fund Management LLC Has $299,000 Stock Holdings in GMS Inc. Get 30 Days of MarketBeat All Access Free, Sign in to your free account to enjoy these benefits. Case 1: Fate Therapeutics stock drops by -5% or more in a week, Case 2: Fate Therapeutics stock rises by 5% or more in a week. NDAQ Fate Therapeutics (NASDAQ:FATE) Rating Increased to Hold at StockNews Receive FATE Stock News and Ratings via Email. FATE stock fares better after Case 1, with an average return of 6% over the next month (21 trading days) under Case 1 (where the stock has just suffered a 5% loss over the previous week), versus, an average return of 3.8% for Case 2. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The firms 50 day moving average is $6.77 and its 200 day moving average is $16.67. The Class A ordinary shares and warrants of BAC trade on the Nasdaq Capital Market under the symbols "BIOT" and "BIOTW," respectively. Fate Therapeutics (NASDAQ:FATE - Get Rating) had its price target upped by equities research analysts at Citigroup from $9.00 to $10.00 in a report issued on Thursday, The Fly reports. Will Boston Scientific Stock See Higher Levels? The definitive agreement will see the payment of up to $1bn to Exonics' equity holders if future development and regulatory milestones are met for certain programmes. Fate Therapeutics (NASDAQ:FATE) Shares Up 7.4% on Earnings Beat baseball font with tail generator. Purchases New Holdings in Ball Co. Kroger (NYSE:KR) Shares Gap Up on Better-Than-Expected Earnings, AlphaCrest Capital Management LLC Trims Position in Best Buy Co., Inc. (NYSE:BBY), AlphaCrest Capital Management LLC Sells 26,238 Shares of Hormel Foods Co. (NYSE:HRL), Burlington Stores, Inc. (NYSE:BURL) Shares Sold by Eaton Vance Management, Tudor Investment Corp Et Al Increases Holdings in Artivion, Inc. (NYSE:AORT), BlackRock Inc. More importantly, there is 60% probability of a positive return over the next twenty-one trading days and a 53% probability of a positive excess return after a -5% change over five trading days, based on historical data. This rating has decreased by -28% over the last 12 months. A class action has already been filed. Our daily ratings and market update email newsletter. Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. The biopharmaceutical company reported ($0.58) earnings per share for the quarter, beating analysts' consensus estimates of ($0.86) by $0.28. The stock was sold at an average price of $5.24, for a total transaction of $38,414.44. Notably, though, the stock is likely to beat S&P500 returns by 4% over the next month (twenty-one trading days). Fate Therapeutics, Inc engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Fate will also be eligible to receive double-digit royalties on worldwide commercial sales of products targeting the antigens. When is Fate Therapeutics' next earnings date? Now, is FATE stock poised to gain further? Shares of Fate Therapeutics were up more than 21% in premarket trading after the company announced a multi-billion dollar deal with Janssen Biotech to develop cell therapies for the treatment of cancer. American Consumer News, LLC dba MarketBeat 2010-2023. How were Fate Therapeutics' earnings last quarter? [] Fate Therapeutics Salaries How much do Fate Therapeutics employees make? Fate Therapeutics Inc Stock - FATE Share Price Today, News and Discussion Fate is working toward a class of treatment that is based on NK cells. While the usual process is to create a different batch for each patient from their own stem cells, Fate is intending for mass production of such treatment. Fates revenue did grow a solid 160% from $4.1 million in 2017 to $10.7 million in 2019. [Updated: 1/20/2021] Is FATE Stock Overbought? Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It has seen positive findings from early trials for FT500, something that has kept the stock price buzzing of late. Will Boston Scientific Stock See Higher Levels? Truist Financial reiterated a hold rating and issued a $7.00 target price (down from $46.00) on shares of Fate Therapeutics in a research note on Friday, January 6th. Export data to Excel for your own analysis. Following the acquisition, the director now owns 246,139 shares in the company, valued at $1,395,608.13. The 16% rise for FATE stock compares with 4% gains seen in the broader S&P 500 index. In comparison, the S&P 500 has an average return of 3.1% over the next 21 trading days under Case 1, and an average return of just 0.5% for Case 2 as detailed in our dashboard that details the average return for the S&P 500 after a fall or rise. Fate Therapeutics, Inc. (FATE) NasdaqGM - NasdaqGM Real Time Price. Hagens Berman is a global plaintiffs' rights complex litigation law firm focusing on corporate accountability through class-action law. The stock price of Fate Therapeutics (NASDAQ: FATE), a biopharmaceuticals company focused on oncology and immunology treatments based on natural killer T-Cell programs, has seen a 9% rise over the last five trading days, and we believe the stock will likely continue to rally in the near term. The revenues are expected to see a sharp jump of over 90% to $20.4 million in 2020, due to collaboration agreements with Janssen and Ono. How Much Does Fate Therapeutics Pay in 2023? (123 Salaries) Fate Therapeutics saw its shares in the red after-hours Thursday night as durability concerns cast a shadow over its latest blood cancer data drop. It didn't provide specific details. It appears so. 1 dividend stock for a LIFETIME of income. Fate TherapeuticsiPSCAR-TCAR-NK | ONO CORPORATE English Global IR See How Its Powering New Collaboration and What-Ifs ForCFOs and Finance Teams |Product, R&D, and Marketing Teams, This is a BETA experience. However, looking at the P/S for Fate is not helpful given the company doesnt have any marketable product yet, and it is more of a story of exciting products in the pipeline. Now that the stock has seen a strong run up over the recent months, and given that the company is far away from any significant revenue growth, we believe that it is vulnerable to downside risk. Can Fate Therapeutics Stock Rebound After A 20% Drop? - Forbes ImmunityBio and NantKwest Complete Merger - ImmunityBio The stock has a market capitalization of $599.76 million, a price-to-earnings ratio of -2.10 and a beta of 1.53.. See what's happening in the market right now with MarketBeat's real-time news feed.